Zinbryta and Demyelination - a phase IV clinical study of FDA data

Summary:

Demyelination is reported as a side effect among people who take Zinbryta (daclizumab), especially for people who are female, 30-39 old, have been taking the drug for 1 - 6 months also take Benadryl, and have Adjustment disorder with depressed mood.

The phase IV clinical study analyzes which people have Demyelination when taking Zinbryta. It is created by eHealthMe based on reports of 2,381 people who have side effects when taking Zinbryta from the FDA, and is updated regularly.

What is Zinbryta?

Zinbryta has active ingredients of daclizumab. eHealthMe is studying from 2,382 Zinbryta users. Check the latest studies of Zinbryta.

What is Demyelination?

Demyelination (loss of the myelin covering of some nerve fibres resulting in their impaired function) is found to be associated with 461 drugs and 670 conditions by eHealthMe. Check the latest studies of Demyelination.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 20, 2026

2,381 people reported to have side effects when taking Zinbryta.
Among them, 14 people (0.59%) have Demyelination.

Among these 14 people:

How long have people been on Zinbryta when they have Demyelination? *

What is the gender of people who have Demyelination when taking Zinbryta? *

female: 100 %
male: 0.0 %

What is the age of people who have Demyelination when taking Zinbryta? *

What are other drugs people take besides Zinbryta? *

Valacyclovir: 3 people, 21.43%
Tylenol: 3 people, 21.43%
Synthroid: 3 people, 21.43%
Percocet: 3 people, 21.43%
Pantoprazole: 3 people, 21.43%
Mayzent: 3 people, 21.43%
Benadryl: 3 people, 21.43%
Piperacillin And Tazobactam: 2 people, 14.29%
Medrol: 2 people, 14.29%
Ampyra: 2 people, 14.29%

What are other side effects people have besides Demyelination? *

Alanine Aminotransferase Increased: 11 people, 78.57%
Aspartate Aminotransferase Increased: 11 people, 78.57%
B-Lymphocyte Count Increased: 11 people, 78.57%
Blood Lactate Dehydrogenase Increased: 11 people, 78.57%
Encephalitis Autoimmune (autoimmune origin disturbances of consciousness and pyramidal signs, inflammation of the brain): 11 people, 78.57%
Oral Candidiasis (fungal infection of mouth): 11 people, 78.57%
Natural Killer Cell Count Decreased (natural killer cell number reduced): 11 people, 78.57%
Loss Of Control Of Legs: 3 people, 21.43%
Gastrointestinal Disorder (functional problems of gastrointestinal tract): 3 people, 21.43%
Hoarseness Or Changing Voice: 3 people, 21.43%

What are the existing conditions these people have? *

Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 11 people, 78.57%
Adjustment Disorder With Depressed Mood: 11 people, 78.57%
Encephalitis Autoimmune (autoimmune origin disturbances of consciousness and pyramidal signs, inflammation of the brain): 8 people, 57.14%
Rickets (softening of bones): 4 people, 28.57%
Progressive Relapsing Multiple Sclerosis (chronic autoimmune disease of the central nervous system in which gradual destruction of myelin occurs in patches throughout the brain or spinal cord or both): 2 people, 14.29%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 14.29%
Hyperthyroidism (over activity of the thyroid gland): 2 people, 14.29%
High Blood Pressure: 2 people, 14.29%
Secondary Progressive Multiple Sclerosis (a stage of ms which comes after relapsing remitting ms in many cases): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Zinbryta and have Demyelination?

- Check whether Demyelination is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zinbryta:

Zinbryta (2,382 reports)

Demyelination treatments and more:

Demyelination (5,739 reports)

Browse all side effects of Zinbryta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Demyelination:

Demyelination (461 drugs)

Browse all the conditions that are associated with Demyelination:

Demyelination (670 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on daclizumab (the active ingredients of Zinbryta) and Zinbryta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.